HK1258507A1 - 改進的p2x7受體結合劑和包含其的多肽 - Google Patents

改進的p2x7受體結合劑和包含其的多肽

Info

Publication number
HK1258507A1
HK1258507A1 HK19100856.2A HK19100856A HK1258507A1 HK 1258507 A1 HK1258507 A1 HK 1258507A1 HK 19100856 A HK19100856 A HK 19100856A HK 1258507 A1 HK1258507 A1 HK 1258507A1
Authority
HK
Hong Kong
Prior art keywords
polypeptides
improved
same
receptor binders
binders
Prior art date
Application number
HK19100856.2A
Other languages
English (en)
Inventor
Marie-Ange Buyse
Catelijne Stortelers
Original Assignee
Ablynx Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ablynx Nv filed Critical Ablynx Nv
Publication of HK1258507A1 publication Critical patent/HK1258507A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
HK19100856.2A 2015-11-12 2019-01-17 改進的p2x7受體結合劑和包含其的多肽 HK1258507A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562254298P 2015-11-12 2015-11-12
PCT/EP2016/077452 WO2017081265A1 (en) 2015-11-12 2016-11-11 Improved p2x7 receptor binders and polypeptides comprising the same

Publications (1)

Publication Number Publication Date
HK1258507A1 true HK1258507A1 (zh) 2019-11-15

Family

ID=57354344

Family Applications (1)

Application Number Title Priority Date Filing Date
HK19100856.2A HK1258507A1 (zh) 2015-11-12 2019-01-17 改進的p2x7受體結合劑和包含其的多肽

Country Status (8)

Country Link
US (1) US10875918B2 (zh)
EP (1) EP3374395A1 (zh)
JP (1) JP7403224B2 (zh)
CN (1) CN108431039B (zh)
AU (1) AU2016352695B2 (zh)
CA (1) CA3005082A1 (zh)
HK (1) HK1258507A1 (zh)
WO (1) WO2017081265A1 (zh)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2746738C2 (ru) 2014-05-16 2021-04-20 Аблинкс Нв Улучшенные вариабельные домены иммуноглобулина

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9260508B2 (en) * 2008-12-19 2016-02-16 Ablynx N.V. Method for generation of immunoglobulin sequences
US20180009888A9 (en) * 2011-06-23 2018-01-11 Ablynx N.V. Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
TW201321405A (zh) 2011-08-17 2013-06-01 Glaxo Group Ltd 經修飾之蛋白質及肽
CN104507964B (zh) * 2012-06-01 2020-05-15 埃博灵克斯股份有限公司 P2x7受体拮抗剂和激动剂
BR122018009619B1 (pt) 2014-05-16 2024-01-02 Ablynx N.V Domínios variáveis de imunoglobulina aperfeiçoados

Also Published As

Publication number Publication date
AU2016352695B2 (en) 2023-07-27
US10875918B2 (en) 2020-12-29
JP7403224B2 (ja) 2023-12-22
EP3374395A1 (en) 2018-09-19
WO2017081265A1 (en) 2017-05-18
AU2016352695A1 (en) 2018-05-24
CA3005082A1 (en) 2017-05-18
CN108431039B (zh) 2022-06-28
JP2019503987A (ja) 2019-02-14
US20180327491A1 (en) 2018-11-15
CN108431039A (zh) 2018-08-21

Similar Documents

Publication Publication Date Title
IL285286A (en) Transpase polypeptides and uses thereof
IL275307B (en) Syntac polypeptides and their uses
HK1254951A1 (zh) Pd1和/或lag3結合劑
IL256121A (en) Adenovirus polynucleotides and polypeptides
IL274751A (en) ILDR2 antagonists and combinations thereof
EP3625300C0 (en) ADHESIVES
GB201707139D0 (en) Polypeptides
GB201410031D0 (en) Polypeptides and uses thereof
HK1252350A1 (zh) Mrka多肽、抗體及其用途
PL3347376T3 (pl) Nowy receptor IGFR-podobny i jego zastosowania
HK1258507A1 (zh) 改進的p2x7受體結合劑和包含其的多肽
PT3250234T (pt) Mdv1 recombinante e suas utilizações
GB201712266D0 (en) polypeptides and uses thereof
GB201712268D0 (en) Polypeptides and uses thereof
IL258042A (en) Tcr and its uses
ZA201708159B (en) Adenovirus polynucleotides and polypeptides
GB201613143D0 (en) Polypeptides and uses thereof
GB201613142D0 (en) Polypeptides and uses thereof
GB201519105D0 (en) Antibody polypeptides and uses thereof
GB201517550D0 (en) Antibody polypeptides and uses thereof
GB201702069D0 (en) Binding polypeptides
GB201511958D0 (en) Polypeptides, polynucleotides and uses thereof
GB201514772D0 (en) Adenovirus polynucleotides and polypeptides
GB201510357D0 (en) Adenovirus polynucleotides and polypeptides
GB201401973D0 (en) Antibody polypeptides and uses thereof